The United States has announced an exemption covering certain speciality medicines and ingredients from a proposed 100% tariff. India is among 20 countries included in the exemption. The coverage includes medicines and products connected with areas such as rare diseases, infertility treatment, cell and gene therapies and other speciality treatments. The development is relevant to India because the country has a large pharmaceutical manufacturing and export sector. Tariff changes can affect the cost and competitiveness of medicines traded between countries, particularly for companies that depend heavily on international markets. The exemption means qualifying Indian pharmaceutical products will not face the full proposed tariff under the specified arrangements. However, the exemption applies to particular categories rather than automatically covering every medicine or pharmaceutical product exported from India. Companies and exporters will therefore need to consider the specific product categories and applicable rules
